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The action of secreted phospholipases A2 in skin is
thought to be essential for epidermal barrier homeo-
stasis. The incomplete knowledge of presence and func-
tions of the novel secreted phospholipase A2 subtypes in
skin prompted us to explore their expression in epider-
mis and primary keratinocytes from murine neonatal
skin. We detected secreted phospholipases A2-IB,
-IIA, -IIC, -IID, -IIE, -IIF, -V, -X, and -XII. To study
secreted phospholipase A2 expression during epidermal
di¡erentiation, primary keratinocytes from the basal,
suprabasal, and upper di¡erentiated layers of neonatal
mouse epidermis were obtained by density gradient
centrifugation. mRNA for secreted phospholipases
A2-IB, -IIE, -IIF, -V, and -XII-1 are mainly expressed
in the upper di¡erentiated layers, whereas the most pro-
minent enzymes in the basal and suprabasal layers are
secreted phospholipases A2-IIA, -IID, and -X. The
mRNA for secreted phospholipase A2-IIC was found
in all fractions. Immunohistochemical analysis in
mouse skin sections re£ected the mRNA distribution
patterns in the di¡erent epidermal cell fractions. After
in vitro induction of keratinocyte di¡erentiation by in-
creasing the calcium concentration of the medium,
secreted phospholipases A2-IB, -IIE, -IIF, -V, and
-XII-1 were upregulated, whereas secreted phospholi-
pases A2-IIA, -IIC, -IID, and -X were mainly expressed
in proliferating keratinocytes. The speci¢c secreted
phospholipase A2 expression pro¢le in the skin suggests
a distinct function for each enzyme in the epidermis.
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D
uring the last few years an increasing number of
phospholipases A2 has been identi¢ed in mamma-
lian tissues (Six and Dennis, 2000; Valentin et al,
2000). These enzymes catalyze the hydrolysis of
the sn-2 ester bond of phospholipid substrates,
thereby producing free fatty acids and lysophospholipids. These
products have important roles in physiologic and pathophysiolo-
gic processes. Of particular importance are eicosanoids, which are
produced from released arachidonic acid and are important med-
iators of vascular tone and tissue homeostasis, but also of pain
and in£ammation. Thus, the knowledge of the expression and
regulation of the di¡erent phospholipases A2 is a prerequisite for
understanding their functions in di¡erent organs and tissues and
for developing speci¢c inhibitors for therapeutic use.
The di¡erent phospholipases A2 are classi¢ed into 12 groups
(I^XII) and have been characterized in terms of their substrate
speci¢cities, Ca2þ sensitivity, and cellular location (for reviews
see Six and Dennis, 2000; Valentin and Lambeau, 2000).
Using these criteria, the phospholipases A2 enzymes identi¢ed
in mammals have been subdivided into the low molecular weight
secreted phospholipases A2 (sPLA2-IB, -IIA, -IIC, -IID, -IIE, -IIF,
-III, -V, -X, and -XII), the group IV cytosolic phospholipases A2,
the group VI Ca2þ -independent phospholipases A2 and the
groupVII and VIII platelet-activating factor acetyl hydrolases.
Analysis of the expression pattern of the di¡erent sPLA2, and
in particular of the novel subtypes of secreted phospholipases
A2 has made clear that more than one sPLA2s subtype can
be expressed in a single tissue or even the same cell, where
sPLA2s might be localized in di¡erent subcellular compartments
(Bingham et al, 1999; Valentin et al, 1999; Degousee et al, 2002). It
is also becoming clear that the mRNA expression of a speci¢c
sPLA2 subtype is not necessarily re£ected by the amount of
expressed protein (Schadow et al, 2001; Gelb et al, unpublished
observations).
The increasing diversity of sPLA2s leads to a number of ques-
tions concerning the functions of these sPLA2s in physiologic and
pathophysiologic processes.
sPLA2s are likely to play a part in normal skin functions. In-
deed, sPLA2 activity is needed for the degradation of polar lipids
in the upper epidermal layers for the generation of fatty acids,
which, together with ceramides, are major components of the
stratum corneum (Elias, 1983; Schˇrer and Elias, 1991). This layer
of apolar lipids is called the permeability barrier, which prevents
transepidermal water loss. The physiologic role of one or several
sPLA2s in barrier integrity became evident from the observation
that inhibition of sPLA2 activity in mouse skin resulted in de-
struction of the epidermal integrity and in transepidermal water
loss (Mao-Qiang et al, 1995, 1996; Fluhr et al, 2001).
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sPLA2s are probably also involved in in£ammatory processes in
the skin, and the knowledge of the expression of sPLA2s is im-
portant for determining among sPLA2s those that are therapeutic
targets in skin in£ammation. In support of a pathophysiologic role
of the so-called proin£ammatory sPLA2-IIA in skin diseases, a
transgenic mouse overexpressing the human sPLA2-IIA developed
hyperkeratosis and hyperplasia, suggesting that human sPLA2-IIA
may act as a growth factor for keratinocytes (Grass et al, 1996);
however, murine sPLA2-IIA is expressed almost exclusively in
small intestine, whereas human sPLA2-IIA is expressed in numer-
ous tissues, suggesting that these two enzymes are not functional
orthologs of each other (Cupillard et al, 1999, and citations here-
in). These results suggest that sPLA2s distinct from sPLA2-IIA
may contribute to murine skin functions and in£ammation.
In a former study, sPLA2-IB and sPLA2-IIAwere identi¢ed in
primary mouse keratinocytes as well as in the keratinocyte carci-
noma cell line HEL 30 and the possible function of these en-
zymes in eicosanoid biosynthesis was addressed (Li-Stiles et al,
1998). Meanwhile several new murine sPLA2 enzymes have been
found in mouse epidermis, although the knowledge of their ex-
pression pattern is still incomplete. A recent study has identi¢ed
sPLA2-IID mRNA in mouse skin (Valentin et al, 1999), and the
expression of sPLA2-IID, -IIE, and -IIF was recently found to be
upregulated during experimental atopic dermatitis in mouse ears
(Murakami et al, 2002a, b, c). Thus, it is not clear which sPLA2
subtype is responsible for the fatty acid release described by
Li-Stiles et al, 1998; Li-Stiles and Fischer, 1999) or involved in the
formation of the permeability barrier. From studies performed in
human keratinocytes (Rys-Sikora et al, 2000; Schadow et al, 2001)
and in human epidermis in vivo (Maury et al, 2000; Mazereeuw-
Hautier et al, 2000), it can be expected that these enzymes are dif-
ferentially regulated at the mRNA and protein level depending
on the proliferation or di¡erentiation state of the epidermis.
This prompted us to analyze sPLA2 subtypes expressed at the
mRNA and protein levels in the di¡erent stages of development
and in the di¡erent layers of the mouse epidermis. A suitable
model system to study the expression and function of epidermal
sPLA2 enzymes is the neonatal mouse skin. This system repre-
sents a hyperplastic phenotype compared with adult epidermis
concerning the morphology, keratin expression, and mitotic ac-
tivity of the cells from the basal layer (Fˇrstenberger et al, 1985).
Because of its multilayered structure, neonatal epidermis o¡ers
the advantage to separate primary keratinocytes by density centri-
fugation using Percoll gradients to study the pattern of sPLA2 ex-
pression in the di¡erent layers. In the present study, we compared
the expression levels of the full set of murine sPLA2s in neoplastic
skin under proliferating and di¡erentiating conditions by using
primary keratinocytes from neonatal skin cultured under low
or high Ca2+ conditions. Moreover, we investigated the pattern
of sPLA2 protein expression in vivo by performing immunohisto-
chemical analysis of neonatal back skin from NMRI mice.
MATERIALS AND METHODS
Preparation of mouse epidermis
Percoll density gradient fractionation of epidermal cells Adult female NMRI
mice together with their neonatal 2 to 3 d old o¡spring were purchased
from Charles River (Sulzfeld, Germany). Neonatal mouse epidermal cells
were obtained by the trypsin £otation method of Yuspa and Harris (1974).
All experiments were carried out according to the guidelines and with per-
mission from the local government of Hessen, Germany. Brie£y, skin
of neonatal mice was incubated for 15 h in plastic Petri dishes containing
10 mL of 0.25% trypsin/phosphate-bu¡ered saline (PBS) without Ca2þ and
Mg2þ (Biochrom, Berlin, Germany). The epidermis was then separated
from the dermis and thoroughly homogenized. The dissociated cells were
loaded onto a Percoll (Fluka, Seelze, Germany) discontinuous gradient ran-
ging from 70% to 30%. Centrifugation at 1900g for 25 min at room tem-
perature yielded four distinct cell fractions with four di¡erent buoyant
densities (Fˇrstenberger et al, 1983; Schweizer et al, 1984). The cell fractions
corresponding to the di¡erent layers were removed and collected separately,
and Percoll was removed by washing two times with PBS without Ca2þ
(Invitrogen, Karlsruhe, Germany) with centrifugation at 600g for 18 min at
room temperature. Induction of di¡erentiation was con¢rmed by semi-
quantitative reverse transcription^polymerase chain reaction (reverse tran-
scription^PCR) of involucrin (data not shown).
Ca2þ shift For cell culture experiments with primary keratinocytes, cells
of the gradient fractions 3 and 4, which represent the proliferative cells of
the basal and suprabasal epidermal layers of the mouse epidermis (Fˇrsten-
berger et al, 1986; Gross et al, 1987), were pooled in 4  minimal essential
medium (Fusenig andWorst, 1974) containing 10% fetal calf serumwith 1.0
mM Ca2þ . Cells (107) were seeded in 100 mm cell culture dishes and in-
cubated in high Ca2þ medium at 341C. After 4 h the medium was chan-
ged to 4  minimal essential medium plus 10% fetal calf serum with 0.05
mMCa2þ (low Ca2þ medium). After an additional 24 h, the mediumwas
changed to high Ca2þ medium. This Ca2þ shift procedure is a standar-
dized method to induce di¡erentiation of proliferating keratinocytes (Hen-
nings et al, 1980, 1989;Yuspa et al, 1989). The cells were harvested as follows:
24 h low Ca2þ medium; 8, 24, 48, and 72 h high Ca2þ medium. Induction
of di¡erentiation was con¢rmed by semiquantitative reverse transcription^
PCR as well as western blot analysis of involucrin (data not shown). The
antibody for involucrin was a generous gift from Dr FionaWatt, Imperial
Cancer Research Fund London (UK).
For RNA isolation, the medium was removed, the cells were washed
twice with ice-cold PBS, and 400 mL of guanidinium isothiocyanate (Sig-
ma, Munich, Germany) was added to each culture dish. Proteins were ex-
tracted from parallel cell culture dishes using 500 mL of homogenization
bu¡er (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfo-
nyl £uoride, 10 mg per mL leupeptin), was added.
Di¡erent layers of the neonatal epidermis The density gradient separated cell
fractions, corresponding to the four di¡erent epidermal layers, were pre-
pared as described above. After washing, cells were directly lyzed in guani-
dinium isothiocyanate for RNA isolation using the guanidinium
isothiocyanate/phenol/chloroform method.
Analysis of sPLA2 mRNA expression by reverse transcription^PCR
RNA extraction Total cellular RNA was extracted from the cell pellets
using the guanidinium isothiocyanate/phenol/chloroform method. To
exclude contamination with DNA, RNA preparations were treated with
RNase-free DNase I (Roche Diagnostics, Mannheim, Germany) for
15 min at room temperature before performing reverse transcription^PCR.
Reverse transcription^PCR The expression of mRNAof the di¡erent sPLA2
subtypes was investigated by reverse transcription^PCR using 5 mg total
RNA. As a positive control, poly(A) RNA from various mouse tissues was
used (Clontech, Heidelberg, Germany). Negative PCR controls were per-
formed on RNA which were not reverse transcribed. First strand cDNA
was transcribed with Superscript II RNase H-RT obtained from Gibco
BRL (Karlsruhe, Germany) and Oligo(dT)15 Primer (Promega, Mannheim,
Germany). Aliquots of the ¢rst strand cDNAwere taken to perform PCR
with the speci¢c primers (Sigma, Karlsruhe, Germany) for each sPLA2
subtype and RedTaq DNA polymerase (Sigma, Munich, Germany). PCR
was performed on a GeneAmp PCR System Thermal Cycler (Amersham
Life Science, Freiburg, Germany) using the following primer pairs:
sPLA2-IBsense: 50 -accccagtggacgacttaga-30; anti-sense: 50 -tcacggtcaca-
gttgcagat-30, ampli¢ed product 197 bp;
sPLA2-IIAsense: 50 -ggctgtgtcagtgcgataaa-30; anti-sense: 50 -tttatcaccg-
ggaaacttgg-30, ampli¢ed product 201 bp;
sPLA2-IICsense: 50 -ccgggatcctagaaaacaca-30; anti-sense: 50 -tgtcccgaac-
atcctctttc-30, ampli¢ed product 200 bp;
sPLA2-IIDsense: 50 -gaaccaccggcctaattaca-30; anti-sense: 50 -gatgaaggta-
ggctgggtca-30, ampli¢ed product 200 bp;
sPLA2-IIEsense: 50 -cctgcgagtgtgacaagaga-30; anti-sense: 50 -atgagtctgc-
tgggagagga-30, ampli¢ed product 206 bp;
sPLA2-IIFsense: 50 -aacactccactggacggaag-30; anti-sense: 50 -gtagcccaca-
aaggacagga-30, ampli¢ed product 203 bp;
sPLA2-Vsense: 50 -ctcacactggcttggttcct-30; anti-sense: 50 -cataacaacggt-
cgtgcatc-30, ampli¢ed product 202 bp;
sPLA2-Xsense: 50 -gtgacgaggagctggcttac-30; anti-sense: 50 -cttggactgcg-
gtgactctc-30, ampli¢ed product 199 bp;
sPLA2-XII-1sense: 50 -gggcaggaacaggaccagacca-30; anti-sense: 50 -ggtt-
tatatccatagcgtgga-30, ampli¢ed product 179 bp;
sPLA2-XII-2sense: 50 -ccacagtggtcctgggaagtactggg-30; anti-sense: 50 -
ggtttatatccatagcgtggaacaggcttcg-30, ampli¢ed product 123 bp;
GAPDHsense: 50 -accacagtccatgccatcac-30; anti-sense: 50 -tccaccaccctgt-
tgctgta-30, ampli¢ed product 452 bp.
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Semi-quantitative reverse transcription^PCR For semiquantitative
reverse transcription^PCR the number of ampli¢cation steps was tested
¢rst for linearity with di¡erent dilutions of reverse transcription product
and di¡erent cycle numbers. Then reverse transcription^PCR for GAPDH
was performed so that equivalent amounts of cDNA could be added to
individual reaction mixtures. The di¡erent cDNA probes were ampli¢ed
in a prepared Mastermix containing deoxyribonucleoside triphosphates,
speci¢c primers and RedTaq-polymerase in the corresponding PCR
bu¡er.
For the PCR reactions the cycling parameters were optimized as follows:
sPLA2-IB: 951C for 1 min (1 cycle) followed by 951C for 50 s, 571C for
30 s and 721C for 20 s (39 cycles);
sPLA2-IIA: 951C for 1 min (1 cycle) followed by 951C for 50 s, 541C for
30 s and 721C for 20 s (40 cycles);
sPLA2-IIC: 951C for 1 min (1 cycle) followed by 951C for 30 s, 541C for
45 s and 721C for 20 s (34 cycles);
sPLA2-IID: 951C for 1min followed by 951C for 50 s, 551C for 30 s and
721C for 20 s. (32 cycles);
sPLA2-IIE: 951C for 1 min (1 cycle) followed by 951C for 50 s, 571C for
30 s and 721C for 20 s (34 cycles);
sPLA2-IIF: 951C for 1 min (1 cycle) followed by 951C for 50 s, 571C for
30 s and 721C for 20 s (31 cycles);
sPLA2-V: 941C for 1 min (1 cycle) followed by 941C for 1 min, 581C for
1 min and 721C for 1 min, 20 s (38 cycles);
sPLA2-X: 951C for 1 min (1 cycle) followed by 951C for 50 s, 591C for
30 s and 721C for 20 s (38 cycles);
sPLA2-XII-1: 951C for 1 min (1 cycle) followed by 951C for 50 s, 571C
for 30 s and 721C for 20 s (38 cycles);
sPLA2-XII-2: 941C for 1min (1 cycle) followed by 941C for 1min, 541C
for 1 min and 721C for 2 min (32 cycles);
GAPDH: 941C for 1 min (1 cycle) followed by 941C for 1 min, 601C for
1 min and 721C for 2 min (24 cycles).
The ¢nal extension phase for the PCR reactions of all subtypes was 10
min at 721C. PCR products were separated on 1% agarose gels containing
0.5 mg ethidium bromide per mL and were visualized with an ultraviolet
gel camera (Biorad, Munich, Germany). After puri¢cation of the PCR
products with a QIAquick PCR puri¢cation kit (Qiagen, Hilden, Ger-
many) the sequences of the di¡erent sPLA2 enzymes were con¢rmed using
a dye terminator DNA sequencing kit in combination with the automated
sequence analyzer A310 (Perkin Elmer Applied Biosystems, Weiterstadt,
Germany).
Western blot analysis For western blot analysis of sPLA2 protein
expression, cell lysates were obtained as described above. The lysates were
soni¢ed for 10 s and centrifugated at 1900g for 5 min at 41C. The
supernatants were removed and the protein concentration was measured
with the Bradford method. One volume containing 50 mg of cellular
protein was precipitated with 0.4 volume of 20% trichloroacetic acid. The
protein pellet was diluted in 10 mL Laemmli sample bu¡er under reducing
(sPLA2-IIA, sPLA2-IIF, sPLA2-V) or nonreducing (sPLA2-IB, sPLA2-IID,
sPLA2-IIE, sPLA2-X, sPLA2-XII) conditions without boiling, and
proteins were separated on a 16% 10  10 cm sodium dodecyl sulfate^
polyacrylamide gel. Proteins were transferred to polyvinyldi£uoride
membranes (Millipore, Eschborn, Germany) for 40 min at 0.8 mA per
cm2. The gel was stained with Coomassie blue, to check for e⁄ciency of
blotting. Nonspeci¢c binding was blocked with NETG^Bu¡er (150 mM
NaCl, 5 mM Ethylenediamine tetraacetic acid, 50 mM Tris/HCl pH 7.5,
0.05% Triton X-100, 0.25% Gelatin) for 30 min at room temperature
followed by incubation for 2 h at room temperature with a 1:150 dilution
of each primary antibody speci¢c against the corresponding mouse sPLA2
subtype. The antibodies were generated by immunization of rabbits with
the recombinant sPLA2 proteins. The procedure of the generation of
recombinant sPLA2 enzymes and the antibodies will be described in a
following publication by Singer et al and was in principle done as
described for the human sPLA2 enzymes (Degousee et al, 2002). By
blotting de¢ned amounts of each recombinant sPLA2 protein and
performing western blot analyses (see below), it was calculated that each
anti-serum is capable of detecting 0.2 to 1 ng of each mouse sPLA2 (with
ECL detection, see below), and does not detect the other mouse sPLA2
enzymes when 50 ng quantities are applied to the Laemmli gel (not
shown). The blots were incubated at room temperature for 1 h with
horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham) at a
dilution of 1:10,000. After washing, peroxidase activity was detected by
developing the blots by the ECL method (Amersham).
Immunohistochemical analysis Total skin cut from the back of
neonatal mice was ¢xed in 4% zinc formalin (Shondon, Pittsburgh,
Pennsylvania) for 16 h and then embedded in para⁄n. To study sPLA2
expression in adult mice, we used cross-sections from the tails, which
consist of a comparable multilayered epidermis as the neonatal skin (data
not shown).
To investigate the expression of the di¡erent subtypes, 4 mm full
thickness biopsies were examined. The para⁄n embedded samples were
depara⁄nized two times in xylene for 5 min. Then, rehydration of the
sections was performed by sequential incubation in 100% and 96%
ethanol (two times each for 10 min), distilled water and equilibration in
PBS. The sections were then digested with proteinase K (1.5 mg per mL;
Qiagen) for 10 min at room temperature. After washing three times with
PBS, samples were blocked for 10 min with serum free blocking bu¡er
obtained from DAKO (Hamburg, Germany) followed by an overnight
incubation at 41C with the speci¢c rabbit anti-mouse anti-serum (dilution
in 2% bovine serum albumin), which were also used for western blotting.
The following dilutions were used for the di¡erent sPLA2 enzymes:
sPLA2-IB (1:50); sPLA2-IIA (1:50); sPLA2-IIC (1:100); sPLA2-IID (1:100);
sPLA2-IIE (1:50); sPLA2-IIF (1:80); sPLA2-V 1:80); sPLA2-X (1:80); sPLA2-
XII (1:50).
For negative control, sections were incubated with 2% bovine serum
albumin without the primary antibody. The sections were then rinsed
three times with PBS and incubated at room temperature for 35 min with
an alkaline phosphatase-conjugated goat anti-rabbit IgG secondary
antibody diluted 1:80 for all sPLA2 subtypes in 2% bovine serum
albumin.
Sections were rinsed as described above, and the alkaline phosphatase
was stained using the DAKO fast red substrate-chromogen system,
containing fast red tablets, bu¡ered substrate, and levamisole. The staining
time, depending on the dilution of the antibodies and sPLA2 subtypes, was
controlled by microscopic observation. Phosphatase-labeled sections were
counterstained with hematoxylin.
Data presentation The preparations of primary keratinocytes and the in
vitro experiments were performed four times with four independent series
of neonatal mice (about 50 animals per series). For immunohistochemical
analysis of each sPLA2 subtype, skin sections from at least ¢ve di¡erent
animals were used.
RESULTS
First, we investigated the expression of sPLA2 mRNA in neona-
tal mouse epidermis, a model system for hyperproliferative skin
(Fˇrstenberger et al, 1985). Neonatal epidermis can be separated
into four di¡erent layers by discontinuous density gradient cen-
trifugation (Schweizer et al, 1984) to give cells from stratum basale
(N4), stratum spinosum (N3), stratum granulosum/corneum
(N2), and upper stratum corneum (N1). The occurrence of sPLA2
enzymes in keratinocytes fractionated according to their state of
di¡erentiation in the di¡erent epidermal layers was investigated.
mRNA for sPLA2-IB, sPLA2-IIF, sPLA2-V, and sPLA2-XII-2
were found to be present in keratinocytes from the upper, di¡er-
entiated cell layers, i.e., in N1 and in N2, whereas these sPLA2s
are barely detectable or even absent in basal keratinocytes from
fractions N3 and N4 (Fig 1A). sPLA2-IIE and sPLA2-XII-1 are
nearly equally well expressed in N1, N2, and N3, but weakly
in N4.
In contrast, mRNA for sPLA2-IIA, sPLA2-IID, and sPLA2-X
was present at higher levels in keratinocytes from N3 and N4
compared with cells from N1 and N2 (Fig 1B). sPLA2-IIC
mRNA did not change across the di¡erent layers of neonatal
epidermis (Fig 1C).
To obtain information about the in vivo protein localization of
the di¡erent sPLA2s, we performed an immunohistochemical
analysis on para⁄n sections of neonatal mouse back skin. Immu-
nostaining of sPLA2-IIF, sPLA2-V, and sPLA2-XII is detectable
mainly in the suprabasal and uppermost layers of the interfolli-
cular epidermis (Fig 2). The basal layer consisting of proliferating
keratinocytes was free of these enzymes. The negative control
without primary antibody was devoid of staining (Fig 2).
A clearly di¡erent expression pattern was found for sPLA2-IIA,
sPLA2-IID, and sPLA2-X (Fig 3). These enzymes are mainly de-
tectable in cells of the basal layer of interfollicular and follicular
epidermis. These results correspond to the mRNA expression
seen in basal keratinocyte fractions (Fig 1A,B). The other sPLA2
158 GURRIERI ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure1. mRNA expression of sPLA2 subtypes expressed in the four fractions of the epidermis of neonatal NMRI mice. Total RNA was
extracted from cells of the four di¡erent epidermal layers N1^N4 obtained by density gradient centrifugation. Semiquantitative reverse transcription^
PCRwas performed with speci¢c primers for each subtype as described in Materials and Methods. GAPDH was used as an internal standard. (A) mRNA
expression of sPLA2-IB, sPLA2-IIE, sPLA2-IIF, sPLA2-V, sPLA2-XII-1, and sPLA2-XII-2, which are upregulated during di¡erentiation. (B) mRNA expres-
sion of sPLA2-IIA, sPLA2-IID, and sPLA2-X, which are downregulated during di¡erentiation. (C) mRNA expression of sPLA2-IIC, which is not regulated.
Abbreviations: N4, stratum basale; N3, stratum spinosum; N2, stratum granulosum; N1, stratum corneum; n.t., no template. A representative of four in-
dependent experiments with similar results is shown.
Figure 2. Immunohistochemistry of sPLA2 subtypes that are mainly expressed in the di¡erentiated layers of murine neonatal epidermis.
Para⁄n-embedded sections of NMRI neonatal back skin were depara⁄nized and incubated with speci¢c primary antibodies against sPLA2-IIF, sPLA2-V,
and sPLA2-X as described in Materials and Methods (original magni¢cation  40). Dilutions were used as follows: sPLA2-IIF and sPLA2-V 1:80; sPLA2-XII
1:50. After incubation with an alkaline phosphatase-conjugated IgG secondary antibody diluted 1:80, the sections were stained with the Dako fast red
substrate-chromogenic system. Negative control corresponds to a stained skin section without primary antibody.
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proteins (IB, IIC, IIE) seem to be expressed weakly throughout
the interfollicular epidermis (Fig 4). A comparable distribution
of the di¡erent epidermal sPLA2s was detected in cross-sections
of the tails of adult NMRI mice (data not shown).
For studying the regulation of sPLA2s during keratinocyte dif-
ferentiation, primary keratinocytes from N3 and N4 were cul-
tured under low or high Ca2þ conditions to either maintain the
proliferation of keratinocytes (0.05 mM) or to induce their di¡er-
entiation (1 mM; Hennings et al, 1980). After di¡erent incubation
periods, cells were analyzed for mRNA expression of the di¡er-
ent sPLA2 subtypes.
As shown in Fig 5(A), a shift to high Ca2þ concentration in-
duced an upregulation of mRNA for sPLA2-IB, sPLA2-IID,
sPLA2-IIE, sPLA2-IIF, and sPLA2-XII-1 with steady-state levels
at 8 h, whereas the sPLA2-V mRNA level increased only at 24 h
after the Ca2þ shift. At later time points, the mRNA levels for
sPLA2-IID, sPLA2-IIE, and sPLA2-Vdecreased, whereas those for
sPLA2-IB, sPLA2-IIF, and sPLA2-XII-1 remain elevated up to 72
h sPLA2-IB was barely detectable after 72 h.
In contrast, mRNA for sPLA2-IIA and sPLA2-Xwere detected
under low Ca2þ conditions and were found to be reduced after
the Ca2þ shift (Fig 6A).
Figure 3. Immunohistochemistry of sPLA2 subtypes that are mainly
expressed in the basal layer in murine neonatal epidermis. The
depara⁄nized sections of NMRI neonatal back skin were incubated with
speci¢c primary antibodies against sPLA2-IIA, sPLA2-IID, and sPLA2-X.
Dilutions were used as follows: sPLA2-IIA 1:50; sPLA2-IID 1:100; and
sPLA2-X 1:80. After incubation with an alkaline phosphatase-conjugated
IgG secondary antibody diluted 1:80 for sPLA2-IIA and 1:100 for sPLA2-IID
and sPLA2-X the sections were stained as described in Fig 2 (original
magni¢cation  40).
Figure 4. Immunohistochemistry of sPLA2 subtypes that are con-
stitutively expressed in the murine epidermis. After depara⁄nization,
the sections of NMRI neonatal back skin were incubated with speci¢c pri-
mary antibodies against sPLA2-IB, sPLA2-IIC, and sPLA2-IIE with a dilu-
tion of 1:50 for sPLA2-IB and sPLA2-IIE and 1:100 for sPLA2-IIC as
described in Materials and Methods. After incubation with an alkaline phos-
phatase-conjugated IgG secondary antibody diluted 1:80, the sections were
stained as described in Fig 2 (original magni¢cation  40).
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The mRNA steady-state level of sPLA2-IIC remained un-
changed in all conditions (Fig 6A).
Despite the detection of the mRNA for sPLA2-XII-2 in the
cell fraction N2 after density centrifugation (Fig 1A), the mRNA
for this subtype was not detectable in primary keratinocytes
under low or high calcium (data not shown). This suggests that
in vivo in neonatal epidermis, sPLA2-XII-2 mRNA is expressed
in a cell type di¡erent from keratinocytes.
Using sPLA2 subtype-speci¢c antibodies, a similar di¡eren-
tiation-dependent expression pattern was found in western
Figure 5. Reverse transcription^PCR (A) and western blot analysis (B) of sPLA2 expression in murine primary keratinocytes, which are
upregulated after Ca2þ shift. Primary keratinocytes were obtained by density gradient centrifugation and cultured under di¡erent Ca2þ concentrations
as described in Materials and Methods. The cells were harvested for RNA and protein extraction after the indicated time points. (A) DNA-free RNAwas
reverse transcribed and subjected to semiquantitative PCR analysis with primer sets speci¢c for sPLA2-IB, sPLA2-IID, sPLA2-IIE, sPLA2-IIF, sPLA2-V, and
sPLA2-XII-1. Each of these sPLA2 are upregulated after shifting the Ca
2+ concentration in the cell culture medium to 1.0 mM. GAPDH was used as an
internal standard. (B) Protein expression of the indicated sPLA2 subtypes was analyzed by probing 50 mg of total protein on western blots, which were
incubated with speci¢c antibodies against each subtype in a dilution of 1:150. Abbreviations: n.t., no template; MW, molecular weight marker. Data are
representative of four independent studies with comparable results.
Figure 6. Semiquantitative reverse transcription^PCR and western blot analysis of sPLA2 mRNA and protein expression in murine primary
keratinocytes that are downregulated after Ca2þ shift. Primary keratinocytes were obtained and cultured as described in Fig 5. (A) DNA-free RNA
was reverse transcribed and subjected to PCR analysis with primer sets speci¢c for sPLA2-IIA, sPLA2-IIC, and sPLA2-X. GAPDH was used as an internal
standard. (B), Protein expression of sPLA2-IIA, sPLA2-IIC, and sPLA2-X was obtained as described in Fig 5. Abbreviations: n.t., no template; MW, mole-
cular weight marker. Data are representative of four independent studies with comparable results.
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blots from keratinocytes cultured under low or high Ca2+
conditions. For each of these anti-sera, 1 ng of the respective
mouse sPLA2 is readily detected (ECL detection) without
giving a signal for all of the other mouse enzymes when tested
at 50 ng.
Consistent with the mRNA levels (Fig 5A), sPLA2-IB,
sPLA2-IID, sPLA2-IIE, sPLA2-IIF, sPLA2-V, and sPLA2-XII
proteins are weakly expressed in keratinocytes cultured in low
Ca2+ medium and increased markedly 8 h after induction of dif-
ferentiation (Fig 5B). At later time points (48 and 72 h) the pro-
tein levels decreased.
In contrast, strong expression of sPLA2-IIA and sPLA2-X pro-
tein was detected in low Ca2+ medium, and that of sPLA2-X
even increased 8 h after the Ca2+ shift; however, 24 h after Ca2+
shift the protein levels were markedly reduced (Fig 6B).
The protein expression pattern for sPLA2-IIC did not appear
to ¢t with the mRNA expression. Indeed, sPLA2-IIC was mainly
found in the basal layer and was decreased in high Ca2þ medium
(Fig 6B). As the mRNA expression appears constant in all
conditions (Fig 6A), the observed decrease in sPLA2-IIC protein
expression in vivo suggests a decrease in protein stability.
DISCUSSION
This study shows that in neonatal mouse epidermis murine
group I, II, V, X, and XII sPLA2 subtypes are expressed at the
mRNA and protein levels. Interestingly, distinct sPLA2 subsets
are expressed in the basal epidermal layer and in the upper di¡er-
entiated layers. In vitro, the regulation of sPLA2 mRNA and pro-
tein expression appears to be strongly dependent on the Ca2+
concentration as found in cultures of primary keratinocytes
isolated from neonatal NMRI mice. sPLA2s expressed in the
basal layer were those found to be expressed under low Ca2+
conditions (0.05 mM), whereas sPLA2s expressed in the suprabasal
layers was detected after Ca2+ increase (1 mM).
One proposed physiologic function of sPLA2s in the normal
skin is that one or more of these enzymes play a part in the
formation of the epidermal permeability barrier by hydrolyzing
polar phospholipids, thus generating free fatty acids at the stra-
tum granulosum/stratum corneum border (Schˇrer and Elias,
1991). It is, however, still unclear, which sPLA2 contribute to bar-
rier function. In studies by Mao-Qiang et al (1995) and Fluhr et al
(2001) using p-bromophenacyl bromide as a general sPLA2 inhi-
bitor and MJ33 as an active-site directed sPLA2 inhibitor, it was
proposed that sPLA2-IB contributes to barrier formation; how-
ever, p-bromophenacyl bromide most likely inhibits several
mouse sPLA2 because it alkylates the active site histidine that is
conserved in all sPLA2s, and MJ33 has recently been shown to
inhibit most of the mouse group I, II, V, and X sPLA2s (Singer
et al, 2002). Thus, the speci¢c sPLA2 involved in barrier formation
remains to be established. Further investigations with more spe-
ci¢c inhibitors as well as detailed localization studies are neces-
sary to determine which of the sPLA2s subtypes are present in
lamellar bodies where they may contribute to fatty acid release
for physiologic barrier functions.
In this study, we have detected mRNA expression for sPLA2-
IB, sPLA2-IIE, sPLA2-IIF, sPLA2-V, and sPLA2-XII-1/-2 in kera-
tinocytes isolated from the di¡erentiated layers (N1 and N2) of
neonatal epidermis by density gradient centrifugation. Thus, one
or more of these sPLA2 appears to be a potential candidate for
generating free fatty acids from phospholipids for formation of
the permeability barrier.
The distribution of mRNA for sPLA2-IB, sPLA2-IIE, sPLA2-
IIF, sPLA2-V, and sPLA2-XII in the di¡erent layers was similar at
the mRNA and protein levels in primary keratinocytes grown in
culture and di¡erentiated with Ca2+ (Hennings et al, 1989; Yuspa
et al, 1989). Interestingly, sPLA2-XII-2 mRNA is found in the
cell fraction N2, but is not expressed in primary keratinocytes
under any conditions studied. sPLA2-XII-2 was so far only found
inT helper type 2 cells (Ho et al, 2001), and thus it is possible that
a cell type other than keratinocytes, being present in the N2 frac-
tion after density gradient centrifugation, might express mRNA
for this sPLA2 subtype; however, it should also be mentioned that
there are no reports showing the existence of mouse sPLA2-XII-2
protein.
Immunohistochemical studies in para⁄n sections of the back
skin of neonatal mice support a suprabasal expression of sPLA2-
IIF, sPLA2-V, and sPLA2-XII protein in vivo. sPLA2-IB and
sPLA2-IIE, which are also upregulated after the Ca
2+ shift, ap-
peared to be weakly expressed throughout the interfollicular epi-
dermis. From these results, we suggest that not only sPLA2-IB,
but also sPLA2 subtypes IIF, V, and XII, which are expressed in
the uppermost layers, may be involved in barrier function. A
more detailed localization study and the use of group speci¢c
sPLA2 inhibitors are necessary to unravel which sPLA2 subtypes
are present in lamellar bodies and contribute to fatty acid release
for physiologic barrier functions.
A di¡erent expression pattern of sPLA2 subtypes was obvious
in keratinocytes from the basal layer. By performing immunohis-
tochemical staining, we have observed a speci¢c basal expression
of sPLA2-IIA, sPLA2-IID, and sPLA2-X in vivo. Interestingly, in
the Ca2+ experiments in vitro, sPLA2-IID and sPLA2-X show an
additional upregulation 8 h after calcium shift. As the Ca2+-
mediated increase in sPLA2-IID and sPLA2-X protein expression
occurs during a relatively early time period after the start of di¡er-
entiation, we suggested that the cells expressing sPLA2-IID and
sPLA2-X still reside in the basal layer and have not yet moved up-
wards to suprabasal cell layers. Similarly, a subpopulation of basal
keratinocytes was shown to express the ‘‘suprabasal’’ keratin 10, a
marker protein of terminal di¡erentiation (Schweizer et al, 1984).
Interestingly, sPLA2-IIC, which was found at high level in testis
and as a pseudogene in humans (Tisch¢eld et al, 1996; Chen et al,
1997), is expressed at the protein level in proliferating primary
keratinocytes in vitro, whereas it is found in vivo in the entire epi-
dermis by immunochemical staining. The decrease in protein le-
vels during terminal di¡erentiation might be due to a more rapid
degradation in vitro as compared with the in vivo situation.
The strong expression of sPLA2-IIA, sPLA2-IID, and sPLA2-X
proteins in the basal layer raises questions regarding their
functions in this layer. Interestingly, mouse sPLA2-IIA, which
was ¢rst identi¢ed as enhancing factor (Mulherkar et al, 1993),
was also found in proliferating cells in the skin and in Paneth
cells of the small intestine (Desai et al, 1991). The enhancing factor
had the property to enhance the binding of epidermal growth
factor to its receptor in the epidermoid carcinoma cell line A431
(Mulherkar et al, 1993), suggesting a role of sPLA2-IIA, and possi-
bly of other sPLA2 proteins, in hyperproliferation of keratino-
cytes. Moreover, the murine sPLA2 enzymes are potentially able
to release arachidonic acid (Singer et al, 2002), and thus, they
might be involved in eicosanoid homeostasis. Mouse sPLA2-X
can release free fatty acids, including arachidonic acid from ad-
herent cells (Hanasaki et al, 1999; Murakami et al, 1999; Bezzine
et al, 2000; Morioka et al, 2000a, b; Saiga et al, 2001), suggesting
that this enzyme may signi¢cantly contribute to eicosanoid for-
mation. sPLA2-IIA as well as sPLA2-IID may also release ara-
chidonic acid from stimulated cells via heparanoid binding
(Murakami et al, 1999, 2002a; for review, see Kudo and Murakami,
2002). Thus, regarding potential functions of basally expressed
sPLA2, it is tempting to speculate that they might be involved in
keratinocyte hyperproliferation during in£ammatory processes.
On the other hand, because of their broad substrate speci¢city,
sPLA2s may also produce fatty acids, such as linoleic acid and
some of its metabolites, which in turn promote anti-in£amma-
tory functions and oppose their e¡ects to those of cPLA2s and
its lipid mediator products (Buckley et al, 1992; Fischer et al, 1996).
We have observed that the expression of some sPLA2s is
modulated in vitro after changing the Ca2+ concentrations of
the medium (sPLA2-IB, sPLA2-IIC, and sPLA2-IIE), whereas
there was no di¡erence in protein expression detectable in
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immunohistochemical staining in epidermis in vivo. The reason
for this discrepancy is currently unknown, but there might be
some additional regulatory factors or di¡erences in mRNA or
protein stability in vivo, which cannot be mimicked in keratino-
cyte cultures by Ca2+ shift.
Furthermore, it cannot be excluded that other sPLA2 subtypes,
which are expressed at low level in the basal layer of normal neo-
natal skin, may be upregulated under in£ammatory conditions.
In this respect, a recent study showed an increased mRNA ex-
pression of sPLA2-IIF in atopic dermatitis induced in the mouse
ear, whereas in normal murine skin, the mRNA for this sPLA2
was not detected (Murakami et al, 2002b). In this study, we could
clearly show that in normal murine skin, sPLA2-IIF mRNA and
protein expression is found mainly in di¡erentiated keratinocytes.
Further studies focusing on the protein expression of sPLA2-IIF
in in£amed mouse skin are mandatory. In other studies, mRNA
expression of sPLA2-IID and sPLA2-IIE was found to be upregu-
lated in mice with experimental atopic dermatitis, but again pro-
tein studies are lacking (Murakami et al, 2002a, c).
The functional role of certain sPLA2 subtypes for eicosanoid
biosynthesis in the skin under in£ammatory conditions in vivo
and in vitro remains to be determined. Interestingly, the di¡eren-
tiation-dependent expression of sPLA2 subtypes correlated with
the expression pattern of eicosanoid-generating enzymes. The
expression of the individual cyclooxygenase-1/2 and lipoxygenase
enzymes in mouse epidermis was also found to be dependent on
the terminal di¡erentiation of keratinocytes (Mˇller-Decker et al,
1998; Heidt et al, 2000). Thus, a concerted action of distinct
sPLA2 subtypes with individual cyclooxygenase or lipoxygenase
isozymes may generate distinct patterns of eicosanoids being
involved in autocrine or paracrine e¡ects of the autacoids. More-
over, it has to be considered that murine sPLA2s might be
secreted and may act in a paracrine fashion on keratinocytes of
other epidermal layers by mediating signal transduction via the
M-type sPLA2 receptor (Cupillard et al, 1999;Yokota et al, 2000).
In summary, we have described a speci¢c expression pattern
for group I, II,V, X, and XII sPLA2s in murine skin. This pattern
is related to the regulation of growth and di¡erentiation, and sug-
gest distinct functions for each sPLA2 subtype in epidermal
homeostasis under both normal and pathologic conditions.
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